Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis

Journal of Clinical Oncology

Volumn 31, Issue 5, 2013, Pages 543-550

  O'Sullivan, Brian ^a   Huang, Shao Hui ^a   Siu, Lillian L ^a   Waldron, John ^a   Zhao, Helen ^b   Perez Ordonez, Bayardo ^c   Weinreb, Ilan ^c   Kim, John ^a   Ringash, Jolie ^a   Bayley, Andrew ^a   Dawson, Laura A ^a   Hope, Andrew ^a   Cho, John ^a   Irish, Jonathan ^b   Gilbert, Ralph ^b   Gullane, Patrick ^b   Hui, Angela ^b   Liu, Fei Fei ^a,b   Chen, Eric ^a   Xu, Wei ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CHEMORADIOTHERAPY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OROPHARYNX CANCER; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RECURRENCE FREE SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ALPHAPAPILLOMAVIRUS; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; ONTARIO; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; RADIOTHERAPY, ADJUVANT; RECURRENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 84875421186     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.0164     Document Type: Article

References (35)

1. Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709-720, 2000 (Pubitemid 30365531)
2. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35, 2010
3. O'Sullivan B, Huang SH, Perez-Ordonez B, et al: Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiother Oncol 103:49-56, 2012
4. Huang SH, Perez-Ordonez B, Liu FF, et al: Atypical clinical behavior of p16-confirmed HPVrelated oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 82:276-283, 2012
5. Spector ME, Gallagher KK, Light E, et al: Matted nodes: Poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status. Head Neck 10.1002/hed.21997 [epub ahead of print on January 13, 2012]
6. Corry J, Peters LJ, Rischin D: Optimising the therapeutic ratio in head and neck cancer. Lancet Oncol 11:287-291, 2010
7. Shi W, Kato H, Perez-Ordonez B, et al: Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 27:6213-6221, 2009
8. Greene FL, Page DL, Fleming ID, et al: AJCC Cancer Staging Manual (ed 6). New York, NY, Springer-Verlag, 2002
9. Sobin L, Wittekind C: Pharynx, International Union Against Cancer (UICC): TNM Classification of Malignant Tumours (ed 6). New York, NY, Wiley- Liss, 2002, pp 27-35
10. Wong K, Huang SH, O'Sullivan B, et al: Point-ofcare outcome assessment in the cancer clinic: Audit of data quality. Radiother Oncol 95:339-343, 2010
11. Warren S, Gates O: Multiple primary malignant tumors: A survey of the literature and a statistical study. Am J Cancer 16:1358-1414, 1932
12. Radiation Therapy Oncology Group: A randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for stage III and IV head and neck carcinomas. http://clinicaltrials.gov/ct2/ show/NCT00265941
13. National Cancer Institute of Canada Clinical Trials Group: Radiation therapy and cisplatin or panitumumab in treating patients with locally advanced stage III or stage IV head and neck cancer (HN6). http://clinicaltrials.gov/ct2/ show/NCT00820248
14. Huang SH, O'Sullivan B, Weinreb I, et al: Patterns of failure and histopathologic outcome predictors following definitive radiotherapy and planned neck dissection with residual disease. Head Neck 34:913-922, 2012
15. Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341-1346, 1995
16. Pintilie M: Analysing and interpreting competing risk data. Stat Med 26:1360-1367, 2007 (Pubitemid 46380846)
17. Brizel DM, Albers ME, Fisher SR, et al: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798-1804, 1998 (Pubitemid 28277960)
18. Peduzzi P, Concato J, Feinstein AR, et al: Importance of events per independent variable in proportional hazards regression analysis: II. Accuracy and precision of regression estimates. J Clin Epidemiol 48:1503-1510, 1995 (Pubitemid 26035533)
19. Rubin DB: Multiple imputation after 18- years. J Am Stat Assoc 91:473-489, 1996
20. Zhang H, Singer B: Analysis of Censored Data: Survival Trees, Recursive Partitioning in the Health Sciences. New York, NY, Springer-Verlag, 1999, pp 93-104
21. Pignon JP, le MaîtreA, Maillard E, et al: Meta- Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4-14, 2009
22. Lassen P, Eriksen JG, Krogdahl A, et al: The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: Evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol 100:49-55, 2011
23. Ang KK, Zhang QE, Rosenthal DI, et al: A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 29: 360s, 2011 (suppl; abstr 5500)
24. Koutcher L, Sherman E, Fury M, et al: Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 81:915-922, 2011
25. Maxwell JH, Kumar B, Feng FY, et al: Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res 16:1226-1235, 2010
26. Farshadpour F, Kranenborg H, Calkoen EV, et al: Survival analysis of head and neck squamous cell carcinoma: Influence of smoking and drinking. Head Neck 33:817-823, 2011
27. Pytynia KB, Grant JR, Etzel CJ, et al: Matchedpair analysis of survival of never smokers and ever smokers with squamous cell carcinoma of the head and neck. J Clin Oncol 22:3981-3988, 2004 (Pubitemid 41079881)
28. Chen AM, Chen LM, Vaughan A, et al: Head and neck cancer among lifelong never-smokers and ever-smokers: Matched-pair analysis of outcomes after radiation therapy. Am J Clin Oncol 34:270-275, 2011
29. Gillison ML, Zhang Q, Jordan R, et al: Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 30:2102-2111, 2012
30. Browman GP, Wong G, Hodson I, et al: Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 328:159-163, 1993 (Pubitemid 23021501)
31. Chen AM, Chen LM, Vaughan A, et al: Tobacco smoking during radiation therapy for headand- neck cancer is associated with unfavorable outcome. Int J Radiat Oncol Biol Phys 79:414-419, 2011
32. Hoff CM, Grau C, Overgaard J: Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma: A prospective study. Radiother Oncol 103:38-44, 2012
33. Trotti A, Gillison M: Phase III trial of radiotherapy plus cetuximab versus chemoradiotherapy in HPVassociated oropharynx cancer. http://clinicaltrials.gov/ct2/show/NCT01302834
34. Haughey BH, Hinni ML, Salassa JR, et al: Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: A United States multicenter study. Head Neck 33:1683-1694, 2011
35. Weinstein GS, Quon H, O'Malley BW Jr, et al: Selective neck dissection and deintensified postoperative radiation and chemotherapy for oropharyngeal cancer: A subset analysis of the University of Pennsylvania transoral robotic surgery trial. Laryngoscope 120:1749-1755, 2010